Nuvation Bio (NYSE:NUVB) Given New $7.00 Price Target at HC Wainwright
Nuvation Bio (NYSE:NUVB – Free Report) had its price objective trimmed by HC Wainwright from $8.00 to $7.00 in a research report released on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock. Several other brokerages have also commented on NUVB. Royal Bank of Canada reissued an outperform rating and […]
More Stories
Procter & Gamble to Cut 7,000 Jobs, Streamline Brands Amid Economic Uncertainty
By Rudy Blalock Procter & Gamble, the world’s largest consumer goods company, on June 5 announced a plan to eliminate...
Tesla Stock Tanks 14 Percent as Trump-Musk Feud Intensifies
By Andrew Moran Shares of Tesla Motors plummeted on June 5 as the feud between Elon Musk and President Donald...
Snowflake (NYSE:SNOW) Price Target Raised to $250.00
Snowflake (NYSE:SNOW – Free Report) had its target price increased by Royal Bank of Canada from $236.00 to $250.00 in...
Defense Stocks To Watch Now – June 2nd
Boeing, GE Aerospace, Citigroup, BigBear.ai, and Lockheed Martin are the five Defense stocks to watch today, according to MarketBeat’s stock...
Promising Fertilizer Stocks To Follow Now – June 2nd
CSX, Union Pacific, Canadian Pacific Kansas City, Norfolk Southern, and Petróleo Brasileiro S.A. – Petrobras are the five Fertilizer stocks...
Wealth Enhancement Advisory Services LLC Has $2.91 Million Stock Holdings in Take-Two Interactive Software, Inc. (NASDAQ:TTWO)
Wealth Enhancement Advisory Services LLC increased its position in shares of Take-Two Interactive Software, Inc. (NASDAQ:TTWO – Free Report) by...